Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?
There is no simple answer to the question: intravenous immunoglobulin-take it or leave it? A thorough review of the current data on mechanisms of action, efficacy, and safety of intravenous immunoglobulins in rheumatic diseases demonstrates that the answer depends on the disease and the patients involved.
Braun-Moscovici
Yolanda
Y
UCLA Medical School, Rheumatology Division, Los Angeles, California 98101, USA.
Furst
Daniel E
DE
D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005544:Forecasting; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D007167:Immunotherapy / Q000592:standards / Q000639:trends; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000188:drug therapy; D009220:Myositis / Q000175:diagnosis / Q000188:drug therapy; D011379:Prognosis; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D012859:Sjogren's Syndrome / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous